nifedipine has been researched along with Proteinuria in 35 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nifedipine GITS was superior to enalapril in controlling ambulatory blood pressure, but they were equivalent in reducing proteinuria (37%)." | 9.08 | Equivalent reduction of proteinuria in hypertensives by either nifedipine GITS or enalapril: disparate effects on neurohormones and ambulatory blood pressure and the influence of salt. ( DeQuattro, V; Lee, DP, 1997) |
| "Our study compared the effects of an angiotensin-converting enzyme inhibitor (captopril) versus a calcium antagonist (nifedipine) on proteinuria and renal function in patients with diabetic nephropathy." | 9.07 | Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. ( Audi, L; Lucas, A; Romero, R; Salinas, I; Sanmarti, A; Teixidó, J, 1992) |
| " Hypertension was treated by nifedipine retard and occasionally by furosemide." | 7.69 | Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation. ( Alivanis, P; Dioudis, C; Goutsaridis, N; Grekas, D; Kalevrosoglou, I; Papoulidou, F; Tourkantonis, A, 1995) |
| " Next, in a randomized double-blind crossover study of 27 subjects with proteinuric CKD, we examined the effects of 6 weeks of treatment with placebo, sitaxentan (endothelin A antagonist), and nifedipine on these peptides alongside the primary end points of proteinuria, blood pressure, and arterial stiffness." | 5.20 | Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism. ( Chariyavilaskul, P; Corder, R; Dhaun, N; Goddard, J; Kimmitt, RA; MacIntyre, IM; Webb, DJ; Wood, EG; Yuzugulen, J, 2015) |
| " We conducted a randomized, double-blind, three-way crossover study in 27 patients with proteinuric CKD to compare the effects of the ET(A) receptor antagonist sitaxentan, nifedipine, and placebo on proteinuria, BP, arterial stiffness, and various cardiovascular biomarkers." | 5.17 | Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. ( Blackwell, S; Dhaun, N; Goddard, J; Johnston, NR; Melville, V; Talwar, DK; Webb, DJ, 2013) |
| " Angiotensin converting enzyme inhibitors (ACE-I) significantly retarded the development of end-stage renal failure compared to antihypertensives other than ACE-I (mostly nifedipine), and the effect was evident particularly in patients with proteinuria below the median (2." | 5.08 | Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. ( Babazono, T; Hirayama, M; Ishii, A; Omori, Y; Takahashi, C; Takeda, M; Tomonaga, O; Ujihara, U; Yokoyama, H, 1997) |
| "Nifedipine GITS was superior to enalapril in controlling ambulatory blood pressure, but they were equivalent in reducing proteinuria (37%)." | 5.08 | Equivalent reduction of proteinuria in hypertensives by either nifedipine GITS or enalapril: disparate effects on neurohormones and ambulatory blood pressure and the influence of salt. ( DeQuattro, V; Lee, DP, 1997) |
| "In a randomized controlled trial 10 patients with renal disease and proteinuria were treated with a dose of 10 mg nifedipine o." | 5.08 | Effects of low-dose nifedipine on urinary protein excretion rate in patients with renal disease. ( Huysmans, FT; Kloke, HJ; Koene, RA; Wetzels, JF, 1998) |
| "At 21 months, both patient groups had similar levels of blood pressure control, however, only the diltiazem group had a change in proteinuria (4+/-10%delta, nifedipine vs." | 5.08 | Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. ( Bakris, GL; Smith, AC; Toto, R, 1998) |
| "Our study compared the effects of an angiotensin-converting enzyme inhibitor (captopril) versus a calcium antagonist (nifedipine) on proteinuria and renal function in patients with diabetic nephropathy." | 5.07 | Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. ( Audi, L; Lucas, A; Romero, R; Salinas, I; Sanmarti, A; Teixidó, J, 1992) |
| " Enalapril and losartan reduced proteinuria but nifedipine did not." | 3.71 | Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency. ( Campbell, DJ; Mackie, FE; Meyer, TW, 2002) |
| "Cyclosporine (CsA) (45 mg/kg/day for 7 days) administration in female Wistar rats induced significant decrease in creatinine clearance (Ccr) and body weight loss (BWL)." | 3.70 | Effect of nifedipine in cyclosporine-induced nephrotoxicity in rats: roles of the thromboxane and endothelin systems. ( Darlametsos, IE; Papanikolaou, EN; Varonos, DD, 2000) |
| "The short-term effects of nifedipine on glomerular hemodynamics, sieving function, and renal tubular function were assessed in 10 patients suffering from biopsy-verified chronic glomerulonephritis." | 3.69 | Contrasting short-term effects of nifedipine on glomerular and tubular functions in glomerulonephritic patients. ( Berg, KJ; Fauchald, P; Hartmann, A; Holdaas, H; Lund, K; Reisaeter, A, 1994) |
| " Hypertension was treated by nifedipine retard and occasionally by furosemide." | 3.69 | Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation. ( Alivanis, P; Dioudis, C; Goutsaridis, N; Grekas, D; Kalevrosoglou, I; Papoulidou, F; Tourkantonis, A, 1995) |
| "In this study we investigated whether the increase in proteinuria induced by an oral protein load may be prevented by the angiotensin-converting enzyme inhibitor (ACEI) captopril in patients with nephrotic syndrome, and whether the effects of captopril on renal haemodynamics and/or glomerular selectivity are comparable to those obtained with the nonsteroidal anti-inflammatory drug (NSAID) indomethacin and the calcium-channel blocker (CaCB) nifedipine." | 3.69 | Renal effects of captopril, indomethacin and nifedipine in nephrotic patients after an oral protein load. ( Allegri, L; Borghetti, A; Buzio, C; Garini, G; Mazzi, A; Mutti, A; Savazzi, G, 1996) |
| "Proteinuria is associated with adverse cardiovascular and renal outcomes that are not prevented by current treatments." | 2.76 | Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. ( Dhaun, N; Goddard, J; Haughie, S; Johnston, NR; Kerr, D; MacIntyre, IM; Melville, V; Webb, DJ, 2011) |
| "Subsequently preeclampsia developed and uteroplacental dysfunction deteriorated." | 1.34 | Severe, early-onset hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome episode with spontaneous remission during pregnancy. ( Gembruch, U; Merz, WM, 2007) |
| "Hypertension was treated with enalapril, enalapril and nifedepine and nifedepine alone." | 1.29 | Proteinuria in essential hypertension. ( Doifode, DV; Kate, SK; Soni, PS, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.86) | 18.7374 |
| 1990's | 21 (60.00) | 18.2507 |
| 2000's | 7 (20.00) | 29.6817 |
| 2010's | 6 (17.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hammoud, SH | 1 |
| Alkhansa, S | 1 |
| Mahjoub, N | 1 |
| Omar, AG | 1 |
| El-Mas, MM | 1 |
| Eid, AA | 1 |
| Alexander, JM | 1 |
| Wilson, KL | 1 |
| Dhaun, N | 4 |
| Yuzugulen, J | 1 |
| Kimmitt, RA | 1 |
| Wood, EG | 1 |
| Chariyavilaskul, P | 1 |
| MacIntyre, IM | 3 |
| Goddard, J | 4 |
| Webb, DJ | 4 |
| Corder, R | 1 |
| Laster, M | 1 |
| Im, D | 1 |
| Ahn, A | 1 |
| Ho, CH | 1 |
| Melville, V | 3 |
| Lilitkarntakul, P | 1 |
| Johnston, NR | 3 |
| Li, J | 2 |
| Li, QX | 2 |
| Xie, XF | 1 |
| Ao, Y | 1 |
| Tie, CR | 1 |
| Song, RJ | 1 |
| Kerr, D | 1 |
| Haughie, S | 1 |
| Blackwell, S | 1 |
| Talwar, DK | 1 |
| Liu, LL | 1 |
| Xia, L | 1 |
| Shao, L | 1 |
| Merz, WM | 1 |
| Gembruch, U | 1 |
| Hartmann, A | 1 |
| Lund, K | 1 |
| Holdaas, H | 1 |
| Fauchald, P | 1 |
| Reisaeter, A | 1 |
| Berg, KJ | 1 |
| Bannister, KM | 1 |
| Weaver, A | 1 |
| Clarkson, AR | 1 |
| Woodroffe, AJ | 1 |
| Soni, PS | 1 |
| Doifode, DV | 1 |
| Kate, SK | 1 |
| Ishimitsu, T | 1 |
| Yagi, H | 1 |
| Ohkubo, M | 1 |
| Nakamura, Y | 1 |
| Yagi, S | 1 |
| Buzio, C | 2 |
| Regolisti, G | 1 |
| Perazzoli, F | 1 |
| Mutti, A | 2 |
| Bergamaschi, E | 1 |
| Borghetti, A | 2 |
| O'Donnell, MJ | 1 |
| Rowe, BR | 1 |
| Lawson, N | 1 |
| Horton, A | 1 |
| Gyde, OH | 1 |
| Barnett, AH | 1 |
| Wilkie, ME | 1 |
| Beer, JC | 1 |
| Raftery, MJ | 1 |
| Dawnay, A | 1 |
| Barton, C | 1 |
| Marsh, FP | 1 |
| Dworkin, LD | 2 |
| Benstein, JA | 1 |
| Parker, M | 2 |
| Tolbert, E | 2 |
| Feiner, HD | 2 |
| Grekas, D | 1 |
| Dioudis, C | 1 |
| Kalevrosoglou, I | 1 |
| Papoulidou, F | 1 |
| Goutsaridis, N | 1 |
| Alivanis, P | 1 |
| Tourkantonis, A | 1 |
| Garini, G | 1 |
| Mazzi, A | 1 |
| Allegri, L | 1 |
| Savazzi, G | 1 |
| Giordano, M | 1 |
| Sanders, LR | 1 |
| Castellino, P | 1 |
| Canessa, ML | 1 |
| DeFronzo, RA | 1 |
| Yokoyama, H | 1 |
| Tomonaga, O | 1 |
| Hirayama, M | 1 |
| Ishii, A | 1 |
| Takeda, M | 1 |
| Babazono, T | 1 |
| Ujihara, U | 1 |
| Takahashi, C | 1 |
| Omori, Y | 1 |
| Hess, B | 1 |
| DeQuattro, V | 1 |
| Lee, DP | 1 |
| Kloke, HJ | 1 |
| Wetzels, JF | 1 |
| Koene, RA | 1 |
| Huysmans, FT | 1 |
| Smith, AC | 1 |
| Toto, R | 1 |
| Bakris, GL | 2 |
| Mehrens, T | 1 |
| Thiele, S | 1 |
| Suwelack, B | 1 |
| Kempkes, M | 1 |
| Hohage, H | 1 |
| Darlametsos, IE | 1 |
| Papanikolaou, EN | 1 |
| Varonos, DD | 1 |
| Mackie, FE | 1 |
| Meyer, TW | 1 |
| Campbell, DJ | 1 |
| Romero, R | 1 |
| Salinas, I | 1 |
| Lucas, A | 1 |
| Teixidó, J | 1 |
| Audi, L | 1 |
| Sanmarti, A | 1 |
| Ferder, L | 1 |
| Daccordi, H | 1 |
| Martello, M | 1 |
| Panzalis, M | 1 |
| Inserra, F | 1 |
| Wang, L | 1 |
| Wang, HY | 1 |
| Tao, WY | 1 |
| Demarie, BK | 1 |
| Eliahou, HE | 1 |
| Cohen, D | 1 |
| Herzog, D | 1 |
| Shechter, P | 1 |
| Serban, I | 1 |
| Kapuler, S | 1 |
| Schiby, G | 1 |
| Gavendo, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| THE EFFECTS OF SITAXSENTAN ONCE DAILY DOSING ON PROTEINURIA, 24-HOUR BLOOD PRESSURE, AND ARTERIAL STIFFNESS IN SUBJECTS WITH CHRONIC KIDNEY DISEASE[NCT00810732] | Phase 2 | 27 participants (Actual) | Interventional | 2007-05-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Carotid-femoral pulse wave velocity (PWV), a measure of arterial stiffness, is determined from the time taken for the arterial pulse to propagate from the carotid to the femoral artery. Baseline was defined as the pre-dose measurement for the measure collected at Week 0 of each treatment period. Week 3 and Week 6 was an average of measurement for the measure collected at Week 3 and 6 of each treatment period. (NCT00810732)
Timeframe: Baseline, Week 3 and 6
| Intervention | Meter per second (Mean) | ||
|---|---|---|---|
| Baseline | Change at Week 3 | Change at Week 6 | |
| Nifedipine | 7.94 | -0.21 | -0.38 |
| Placebo | 7.74 | -0.21 | 0.29 |
| Sitaxsentan | 7.97 | -0.19 | -0.41 |
Mean urine total protein assessment included 24-hour urine collections to assess total protein excretion per 24 hours. Baseline was derived from an average of Week 0 (pre-dose) 24-hour urine collections prior to each treatment period. Week 6 was derived from an average of Week 6 24-hour urine collections for each treatment period. (NCT00810732)
Timeframe: Baseline, Week 6
| Intervention | Grams per 24 hours (Mean) | |
|---|---|---|
| Baseline | Change at week 6 | |
| Nifedipine | 1.95 | 0.01 |
| Placebo | 2.07 | -0.06 |
| Sitaxsentan | 2.07 | -0.62 |
The 24-hour ambulatory BP monitoring was performed by using a BP cuff which was attached to the participant's arm, using the same arm throughout the study, with a small monitor that comfortably sits in the pocket of participant. Mean values over 24-hour measurements at each measurement period were calculated. The change in total 24-hour ambulatory monitoring of systemic arterial BP, SBP and DBP at Week 3 and 6 relative to baseline were reported. Baseline was as an average of the pre-dose measurement for the measure collected at Week 0 of each treatment period. Week 3 and Week 6 was an average of measurement for the measure collected at Week 3 and 6 of each treatment period. (NCT00810732)
Timeframe: Baseline, Week 3 and 6
| Intervention | Millimeter of Mercury (mmHg) (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean Systemic Arterial BP: Baseline | Mean Systemic Arterial BP: Change at Week 3 | Mean Systemic Arterial BP: Change at Week 6 | Mean Systemic Arterial SBP :Baseline | Mean Systemic Arterial SBP: Change at Week 3 | Mean Systemic Arterial SBP: Change at Week 6 | Mean Systemic Arterial DBP: Baseline | Mean Systemic Arterial DBP: Change at Week 3 | Mean Systemic Arterial DBP: Change at Week 6 | |
| Nifedipine | 93.78 | -2.95 | -3.54 | 125.12 | -4.20 | -4.47 | 78.27 | -2.09 | -2.86 |
| Placebo | 92.98 | -1.20 | -0.35 | 125.17 | -2.81 | -1.57 | 77.58 | -0.86 | -0.41 |
| Sitaxsentan | 92.94 | -4.59 | -3.74 | 124.03 | -4.88 | -3.99 | 77.56 | -4.85 | -3.60 |
1 review available for nifedipine and Proteinuria
| Article | Year |
|---|---|
Hypertensive emergencies of pregnancy.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Creatine; Diuretics; Emergency Medicine; Female; | 2013 |
16 trials available for nifedipine and Proteinuria
| Article | Year |
|---|---|
Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism.
Topics: Adult; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method | 2015 |
Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease.
Topics: Adult; Aged; Antihypertensive Agents; Arteries; Blood Pressure; Calcium Channel Blockers; Cross-Over | 2009 |
Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease.
Topics: Adult; Antihypertensive Agents; Arteries; Blood Pressure; Cross-Over Studies; Double-Blind Method; D | 2011 |
Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.
Topics: Adult; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; | 2013 |
Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy.
Topics: Aldosterone; Blood Pressure; Combined Modality Therapy; Diet, Sodium-Restricted; Disease Progression | 1995 |
Renal effects of nifedipine and captopril in patients with essential hypertension and reduced renal reserve.
Topics: Adult; Captopril; Diuresis; Female; Hemodynamics; Humans; Hypertension; Kidney; Male; Middle Aged; N | 1994 |
Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B | 1993 |
Effect of nifedipine on renal haemodynamics and urinary protein excretion in stable renal transplant recipients.
Topics: Adult; Azathioprine; Blood Pressure; Creatinine; Cyclosporine; Female; Follow-Up Studies; Glomerular | 1993 |
Effect of alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients.
Topics: Adrenergic alpha-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood | 1996 |
Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 1997 |
Equivalent reduction of proteinuria in hypertensives by either nifedipine GITS or enalapril: disparate effects on neurohormones and ambulatory blood pressure and the influence of salt.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Monitoring, Ambulator | 1997 |
Effects of low-dose nifedipine on urinary protein excretion rate in patients with renal disease.
Topics: Adult; beta 2-Microglobulin; Calcium Channel Blockers; Delayed-Action Preparations; Female; Glomerul | 1998 |
Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy.
Topics: Adult; Aged; Calcium Channel Blockers; Diabetic Nephropathies; Diltiazem; Female; Humans; Kidney Glo | 1998 |
Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients.
Topics: Blood Glucose; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glyc | 1992 |
Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Creatinine; Diab | 1992 |
Effects of different calcium antagonists on proteinuria associated with diabetes mellitus.
Topics: Aged; Creatinine; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Di | 1990 |
18 other studies available for nifedipine and Proteinuria
| Article | Year |
|---|---|
Molecular basis of the counteraction by calcium channel blockers of cyclosporine nephrotoxicity.
Topics: Animals; Biomarkers; Blood Urea Nitrogen; Calcium Channel Blockers; Collagen Type IV; Creatinine; Cy | 2018 |
A 12-year-old boy with dyspnea, hypertension, hematuria, and proteinuria.
Topics: Child; Diagnosis, Differential; Dyspnea; Furosemide; Glomerulonephritis; Hematuria; Humans; Hyperten | 2015 |
Differential roles of dihydropyridine calcium antagonist nifedipine, nitrendipine and amlodipine on gentamicin-induced renal tubular toxicity in rats.
Topics: Acetylglucosaminidase; Amlodipine; Animals; Apoptosis; bcl-2-Associated X Protein; Blood Urea Nitrog | 2009 |
Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats.
Topics: Amlodipine; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Blood Urea Nitrogen; Calci | 2007 |
Severe, early-onset hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome episode with spontaneous remission during pregnancy.
Topics: Adult; Antihypertensive Agents; Female; Fetal Death; HELLP Syndrome; Humans; Methyldopa; Nifedipine; | 2007 |
Contrasting short-term effects of nifedipine on glomerular and tubular functions in glomerulonephritic patients.
Topics: Adult; Aged; Albuminuria; Blood Pressure; Chronic Disease; Dextrans; Female; Glomerular Filtration R | 1994 |
Proteinuria in essential hypertension.
Topics: Adult; Aged; Colorimetry; Creatinine; Drug Combinations; Enalapril; Humans; Hypertension; Middle Age | 1994 |
Different effects between antihypertensive drugs on nephrotic-range proteinuria in renovascular hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biso | 1994 |
Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Enalapril; Glomeruloscl | 1993 |
Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Creatinine; Delayed-Actio | 1995 |
Renal effects of captopril, indomethacin and nifedipine in nephrotic patients after an oral protein load.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflam | 1996 |
Reduced proteinuria after cessation of long-acting, osmotic release nifedipine GITS in diabetic nephropathy.
Topics: Aged; Calcium Channel Blockers; Delayed-Action Preparations; Diabetic Nephropathies; Female; Humans; | 1997 |
The beneficial effects of calcium channel blockers on long-term kidney transplant survival are independent of blood-pressure reduction.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Creatinine; Follow-Up Studies; Gr | 2000 |
Effect of nifedipine in cyclosporine-induced nephrotoxicity in rats: roles of the thromboxane and endothelin systems.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Body Weight; Calcium Channel Blockers; Creatinine; Cyclospori | 2000 |
Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykin | 2002 |
[The influence of hypertension and antihypertensive agents on experimental IgA nephropathy (IgAN)].
Topics: Angiotensin II; Animals; Blood Pressure; Captopril; Female; Glomerulonephritis, IGA; Hypertension, R | 1991 |
Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR.
Topics: Animals; Blood Pressure; Enalapril; Kidney Glomerulus; Longitudinal Studies; Nephrectomy; Nifedipine | 1991 |
The control of hypertension and its effect on renal function in rat remnant kidney.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Creatinine; Dietary Proteins; Dihydralazine; Fema | 1988 |